- Industry Survey 2015
- Articles by Topic
- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- News & Blog
Ryzodeg® passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan
3 December 2012 • Author: Novo Nordisk
Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan’s Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare.
The First Committee on Drugs of Pharmaceutical Affairs serves as an advisory body to the Ministry in matters related to pharmaceuticals including new drug applications. The passing of the review by the drug committee is an essential milestone in the Japanese review process prior to a marketing authorisation from the Ministry.
Novo Nordisk expects to receive marketing authorisation from the Ministry within a few months.
In Japan, price negotiations for Tresiba® (insulin degludec) continue and are expected to be completed in the first quarter of 2013. The exact launch timing for Ryzodeg® is to be decided after the Tresiba® price listing.
About Tresiba® and Ryzodeg®
Tresiba® is the intended brand name for insulin degludec, the first once-daily newgeneration basal insulin analogue, with an ultra-long duration of action, discovered and developed by Novo Nordisk. Tresiba® has a distinct slow absorption which provides a flat and stable action profile. Tresiba® has been studied in a large-scale clinical trial programme, BEGIN™, examining its impact on glucose control, hypoglycaemia and the possibility to flexibly adjust Tresiba® dosing time to suit patient needs.
Ryzodeg® is the intended brand name for insulin degludec/insulin aspart, which contains the new-generation basal insulin degludec in a formulation with a bolus boost of insulin aspart. Ryzodeg® is the first and only soluble insulin combination of ultra-long-acting insulin degludec and the most prescribed rapid-acting insulin, NovoRapid® (NovoLog® in the US), providing both fasting and post-prandial glucose control. Tresiba® and Ryzodeg® were submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) in December 2011 and March 2012, respectively. Tresiba® was approved in Japan in September 2012 and in October 2012 Tresiba® and Ryzodeg® received positive CHMP opinions in Europe. In November, the products received a positive vote for approval from an FDA Advisory Committee. In addition, applications have been submitted for regulatory approval in Canada, Switzerland and a range of other countries.
ABB Analytical Measurement ABS Laboratories Analytik Jena AG Axis-Shield Diagnostics Ltd Black Swan Analysis Limited CAMO Software AS Celsis International Cherwell Laboratories CI Precision Cobalt Light Systems Comark Instruments Coulter Partners Dotmatics Limited Enterprise System Partners EUROGENTEC GE Analytical Instruments HunterLab Hyglos GmbH IONICON Analytik GmbH kbiosystems ltd LabWare MKS Umetrics Portalis Ltd Powder Systems Limited (PSL) RADWAG Reach Separations ReAgent Source BioScience Spectrum®Labs.com Stratech Scientific Limited Thermal Detection Ltd. Thermo Fisher Scientific Tuttnauer Vaisala Ltd VIAVI OSP Waters Corporation Wickham Laboratories Limited Xylem Analytics Ytron-Quadro (UK) Limited Yusen Logistics